The FDA recorded a supplement to an abbreviated new drug application for risperidone from a generic manufacturer. This is a manufacturing or administrative change to an already-approved generic antipsychotic, not a new indication, formulation or safety communication.
Risperidone has been off-patent and widely used for years, and nothing in this record changes how it should be prescribed or monitored. It does not signal a new benefit or a new risk.
In Indian practice risperidone is a long-established, low-cost generic across schizophrenia and bipolar disorder, so this US administrative action has no direct bearing here. It is noted for completeness rather than for any change to care.
- The action is a supplement to a generic (abbreviated) application for risperidone.
- It is a manufacturing or administrative change, not a new indication or safety alert.
- Prescribing, dosing and monitoring of risperidone are unchanged.
- Risperidone is a long-established low-cost generic in India; this US record has no direct local effect.
Why it matters
It is worth distinguishing a routine generic supplement from the approvals and safety actions that do change prescribing.
Don't overread it
This is an administrative regulatory record, not a safety finding or a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free